Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents.

A number of small-molecule poly (ADP-ribose) polymerase (PARP) inhibitors are currently undergoing advanced clinical trials. Determining the distribution and target inhibitory activity of these drugs in individual subjects, however, has proven problematic. Here, we used a PARP agent for positron emission tomography-computed tomography (PET-CT) imaging ((18)F-BO), which we developed based on the Olaparib scaffold using rapid bioorthogonal conjugation chemistries. We show that the bioorthogonal (18)F modification of the parent molecule is simple, highly efficient, and well tolerated, resulting in a half maximal inhibitory concentration (IC(50)) of 17.9 ± 1.1 nM. Intravital imaging showed ubiquitous distribution of the drug and uptake into cancer cells, with ultimate localization within the nucleus, all of which were inhibitable. Whole-body PET-CT imaging showed tumoral uptake of the drug, which decreased significantly, after a daily dose of Olaparib. Standard (18)F-fludeoxyglucose imaging, however, failed to detect such therapy-induced changes. This research represents a step toward developing a more generic approach for the rapid codevelopment of companion imaging agents based on small-molecule therapeutic inhibitors.

[1]  J. A. Hendricks,et al.  Synthesis of [18F]BODIPY: bifunctional reporter for hybrid optical/positron emission tomography imaging. , 2012, Angewandte Chemie.

[2]  J. Thigpen.  Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer , 2012 .

[3]  H. Mackay,et al.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.

[4]  P. Conti,et al.  Rapid aqueous [18F]-labeling of a bodipy dye for positron emission tomography/fluorescence dual modality imaging. , 2011, Chemical communications.

[5]  Ralph Weissleder,et al.  Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. , 2011, Cancer research.

[6]  R. Weissleder,et al.  High‐Yielding, Two‐Step 18F Labeling Strategy for 18F‐PARP1 Inhibitors , 2011, ChemMedChem.

[7]  D. Perrais,et al.  A High Precision Survey of the Molecular Dynamics of Mammalian Clathrin-Mediated Endocytosis , 2011, Microscopy and Microanalysis.

[8]  R. Weissleder,et al.  Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method. , 2011, Angewandte Chemie.

[9]  Ralph Weissleder,et al.  Intravital Imaging , 2011, Cell.

[10]  R. Weissleder,et al.  Bioorthogonal Small‐Molecule Ligands for PARP1 Imaging in Living Cells , 2010, Chembiochem : a European journal of chemical biology.

[11]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[12]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Kaufmann,et al.  PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.

[14]  Eric F. Johnson,et al.  Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor. , 2010, Journal of Medicinal Chemistry.

[15]  M. Robson,et al.  Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer. , 2010, Oncology.

[16]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[17]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[18]  M. V. Heiden,et al.  Cancer's insatiable appetite , 2009, Nature Biotechnology.

[19]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[20]  Stephanie Alexander,et al.  Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model , 2008, Histochemistry and Cell Biology.

[21]  A. Lau,et al.  4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. , 2008, Journal of medicinal chemistry.

[22]  J. Low,et al.  Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology , 2007, Clinical Cancer Research.

[23]  M. Makale.  Intravital imaging and cell invasion. , 2007, Methods in enzymology.

[24]  K. Messmer,et al.  Dorsal skinfold chamber technique for intravital microscopy in nude mice. , 1993, The American journal of pathology.

[25]  E. Rofstad,et al.  A transparent chamber for the dorsal skin fold of athymic mice. , 1984, Experimental cell biology.